bluuebunny/crossref_metadata_2025_split huggingface dataset:
Impact of pain sensitisation on the quality of life of patients with knee osteoarthritis
Authors: Aw Natalie Min-Yi , Yeo Seng-Jin , Wylde Vikki , Wong Steven B , Chan Diana , Thumboo Julian , Leung Ying Ying 
Published: March 2022

ObjectivesWe aim to evaluate the effect on different ways of classifying pain sensitisation on impact and quality of life (QoL) in knee osteoarthritis (KOA).MethodsWe used baseline data from a cohort of consecutive patients with KOA listed for arthroplasty. We collected demographics and number of painful body sites. We measured pressure pain thresholds at the right forearm (PPTarm). Pain sensitisation was classified using: (1) widespread pain, (2) lowest 10th percentile of PPTarm and (3) PainDETECT questionnaire ≥13/38. Impact and QoL were assessed using Western Ontario and McMaster Universities Osteoarthritis Index and Short Form-36. Impact and QoL scores in patients with or without pain sensitisation were compared. We evaluated the association of pain sensitisation measures with QoL scores using multivariable regression.Results233 patients (80% female, mean age 66 years) included in the analysis; 7.3%, 11.6% and 4.7% were classified as having pain sensitisation by widespread pain, low PPTarm and PainDETECT criteria, respectively. There was minimal overlap of patients as classified as pain sensitisation phenotype by different measures. Patients with pain sensitisation had poorer QoL compared with those without. Low PPTarm identified patients with poorer general health, while widespread pain and PainDETECT identified poorer QoL in more psychological domains. There was weak correlation between number of painful body sites and PainDETECT (rho=0.23, p<0.01), but no significant correlation with PPTarm.ConclusionPatients with KOA with pain sensitisation have poorer QoL compared with those without, regardless of classification method. Different criteria defined patients with different pattern of QoL impact.
Association between long-term exposure to air pollution and immune-mediated diseases: a population-based cohort study
Authors: Adami Giovanni , Pontalti Marco , Cattani Giorgio , Rossini Maurizio , Viapiana Ombretta , Orsolini Giovanni , Benini Camilla , Bertoldo Eugenia , Fracassi Elena , Gatti Davide , Fassio Angelo 
Published: March 2022

ObjectiveEnvironmental air pollution has been associated with disruption of the immune system at a molecular level. The primary aim of the present study was to describe the association between long-term exposure to air pollution and risk of developing immune-mediated conditions.MethodsWe conducted a retrospective observational study on a nationwide dataset of women and men. Diagnoses of various immune-mediated diseases (IMIDs) were retrieved. Data on the monitoring of particulate matter (PM)10 and PM2.5 concentrations were retrieved from the Italian Institute of Environmental Protection and Research. Generalised linear models were employed to determine the relationship between autoimmune diseases prevalence and PM.Results81 363 subjects were included in the study. We found a positive association between PM10 and the risk of autoimmune diseases (ρ+0.007, p 0.014). Every 10 µg/m3 increase in PM10 concentration was associated with an incremental 7% risk of having autoimmune disease. Exposure to PM10 above 30 µg/m3 and PM2.5 above 20 µg/m3 was associated with a 12% and 13% higher risk of autoimmune disease, respectively (adjusted OR (aOR) 1.12, 95% CI 1.05 to 1.20, and aOR 1.13, 95% CI 1.06 to 1.20). Exposure to PM10 was associated with an increased risk of rheumatoid arthritis; exposure to PM2.5 was associated with an increased risk of rheumatoid arthritis, connective tissue diseases (CTDs) and inflammatory bowel diseases (IBD).ConclusionLong-term exposure to air pollution was associated with higher risk of developing autoimmune diseases, in particular rheumatoid arthritis, CTDs and IBD. Chronic exposure to levels above the threshold for human protection was associated with a 10% higher risk of developing IMIDs.
Trends in orthopaedic surgery for spondyloarthritis: outcomes from a National Hospitalised Patient Registry (MBDS) over a 17-year period (1999–2015).TREND-EspA study
Authors: Mazzucchelli Ramón , Almodóvar Raquel , Turrado-Crespí Paula , Crespí-Villarías Natalia , Pérez-Fernández Elia , García-Zamora Elena , García-Vadillo Alberto 
Published: March 2022

ObjectiveTo assess the incidence of orthopaedic surgery (OS) (including total hip arthroplasty (THA), total knee arthroplasty, upper limb arthroplasty, arthrodesis and spinal surgery) and associated trends in patients with spondyloarthritis (SpA) over a long period (17 years).MethodsAn observational, retrospective, population-based, serial cross-sectional study was conducted. All hospital admissions of patients with SpA reported between 1999 and 2015 were analysed, and a control group was selected and matched by age, sex and year of admission. Incidence rates for OS (and subtypes) were calculated. Generalised linear models were used to analyse trends; unconditional logistic regression models were used to calculate crude and adjusted ORs (aORs) with the aim of evaluating the association between OS and SpA.ResultsThe study database contained data on 214 280 hospital admissions (SpA/non-SpA 1:1 ratio). In the SpA cohort, 5 382 admissions (5.02%) had undergone OS compared with 3 533 in the non-SpA cohort (3.29%) (AOR 1.64; 95% CI 1.57 to 1.72). OS rates increased for both cohorts (+4.92% per year vs +8.41%). The trend in OS, THA, arthrodesis and spinal surgery decreased or stabilised in patients under age 60 in the SpA cohort, while the non-SpA cohort remained stable. In the SpA cohort, the mean age was 53.68 years (SD 13.65) in 1999, increasing to 62.76 years (SD 12.74) in 2015. In the non-SpA cohort, the mean age remained stable at around 63 years.ConclusionsA 9-year difference in the age of patients undergoing OS was observed in patients with SpA. The incidence of OS, THA and arthrodesis decreased in patients under age 60, and the incidence of spinal surgery decreased in patients under age 40. Our findings suggest that these patients are increasingly able to defer surgical interventions.
Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd study
Authors: van der Heijde Désirée , Gensler Lianne S , Maksymowych Walter P , Landewé Robert , Rudwaleit Martin , Bauer Lars , Kumke Thomas , Kim Mindy , Auteri Simone Emanuele , Hoepken Bengt , Deodhar Atul 
Published: March 2022

Background52-week results from C-axSpAnd demonstrated the safety and efficacy of certolizumab pegol (CZP) in patients with active non-radiographic axial spondyloarthritis (nr-axSpA) and objective signs of inflammation (sacroiliitis on MRI and/or elevated C-reactive protein levels). Long-term safety and clinical outcomes, including MRI assessments, are evaluated up to 3 years for CZP-treated patients with nr-axSpA.MethodsC-axSpAnd was a phase 3 study comprising a 1-year double-blind, placebo-controlled period and 2-year open-label safety follow-up extension (SFE). At baseline, 317 patients were randomised 1:1 to placebo or CZP 200 mg every 2 weeks. Patients completing the double-blind phase who enrolled into the SFE received open-label CZP for an additional 104 weeks. Long-term safety and clinical outcomes are reported to Week 156. Continuous outcomes are presented as observed case (OC) and dichotomous outcomes as OC and with non-responder imputation.Results243/317 (76.7%) patients entered the SFE, during which 149 (61.3%) experienced ≥1 treatment-emergent adverse event (TEAE); 15 (3.3/100 patient-years) experienced serious TEAEs. Continuous outcome scores (including Ankylosing Spondylitis Disease Activity Score [ASDAS]: 1.8; Bath Ankylosing Spondylitis Disease Activity Index [BASDAI]: 2.7) at Week 52 were maintained at Week 156 (ASDAS: 1.8; BASDAI: 2.6) for the initial CZP-randomised group. Mean SPARCC MRI sacroiliac joint inflammation scores for these patients decreased at Week 52 (baseline: 7.6; Week 52: 1.7), remaining low at Week 156 (2.4).ConclusionsCZP treatment was well tolerated up to 3 years, with no new safety signals versus previous reports. Clinical outcomes achieved after 1 year were sustained to 3 years.Trial registration numberNCT02552212.
When the world stops: The impact of COVID-19 on physical activity and physical literacy
Authors: Houser Natalie E. , Humbert M. Louise , Kriellaars Dean , Erlandson Marta C. 
Published: March 2022

Matched pre-during pandemic comparison (160 children) revealed a substantial reduction in physical activity (p < 0.001, rrb = 0.83), environmental participation (p = 0.046, rrb = 0.16), movement valuation (p < 0.001, rrb = 0.61), and parent perceptions of children’s physical literacy (p < 0.001, rrb = 0.56). Examining physical activity trajectories, higher pre-pandemic physical literacy protected children from pandemic related activity decline. Emerging from the pandemic, interventions should address children’s eroded belief in movement and consider physical literacy levels of children in individualizing movement opportunities for restoration of activity levels. Novelty: A substantial reduction in physical activity was associated with children who had lower physical literacy and resulted in reductions in children’s valuation of movement.
Drivers of at-vessel mortality of the blue shark (Prionace glauca) and oceanic whitetip shark (Carcharhinus longimanus) assessed from monitored pelagic longline experiments
Authors: Massey Yoluène , Sabarros Philippe S. , Bach Pascal 
Published: March 2022

Elasmobranchs make up a significant part of bycatch in pelagic longline fisheries, whose induced mortality can be a major threat to endangered species. It is therefore crucial to understand the drivers of at-vessel mortality (AVM) for this fishing gear to enhance postrelease survival. To this end, we analysed scientific data collected during monitored longline fishing experiments conducted in French Polynesia to ( i) estimate AVM for each species based on bootstrapped samples and ( ii) to assess AVM drivers using multivariate logistic regression models for the blue shark ( Prionace glauca) and oceanic whitetip shark ( Carcharhinus longimanus). We found that AVM varies widely between species. Oceanic whitetip sharks are more likely to die when caught in waters outside their comfort temperature range, and their odds of survival increase with body length. For the blue shark, the only driver related to AVM is hooking duration. These results indicate that to reduce the AVM of these two species, the vertical distribution of hooks and soak duration should be considered as mitigation measures related to pelagic longlining.
Accelerator commissioning and rare isotope identification at the Facility for Rare Isotope Beams
Authors: Wei J. , Ao H. , Arend B. , Beher S. , Bollen G. , Bultman N. , Casagrande F. , Chang W. , Choi Y. , Cogan S. , Compton C. , Cortesi M. , Curtin J. , Davidson K. , Du X. , Elliott K. , Ewert B. , Facco A. , Fila A. , Fukushima K. , Ganni V. , Ganshyn A. , Gao J. , Glasmacher T. , Guo J. , Hao Y. , Hartung W. , Hasan N. , Hausmann M. , Holland K. , Hseuh H. C. , Ikegami M. , Jager D. , Jones S. , Joseph N. , Kanemura T. , Kim S.-H. , Knudsen P. , Kortum B. , Kwan E. , Larter T. , Laxdal R. E. , Larmann M. , Laturkar K. , LeTourneau J. , Li Z.-Y. , Lidia S. , Machicoane G. , Magsig C. , Manwiller P. , Marti F. , Maruta T. , McCartney A. , Metzgar E. , Miller S. , Momozaki Y. , Morris D. , Mugerian M. , Nesterenko I. , Nguyen C. , O’Brien W. , Openlander K. , Ostroumov P. N. , Patil M. , Plastun A. S. , Popielarski J. , Popielarski L. , Portillo M. , Priller J. , Rao X. , Reaume M. , Ren H. , Saito K. , Smith M. , Steiner M. , Stolz A. , Tarasov O. B. , Tousignant B. , Walker R. , Wang X. , Wenstrom J. , West G. , Witgen K. , Wright M. , Xu T. , Xu Y. , Yamazaki Y. , Zhang T. , Zhao Q. , Zhao S. , Dixon K. , Wiseman M. , Kelly M. , Hosoyama K. , Prestemon S. 
Published: March 2022

In 2008, Michigan State University was selected to establish the Facility for Rare Isotope Beams (FRIB). Construction of the FRIB accelerator was completed in January 2022. Phased accelerator commissioning with heavy ion beams started in 2017 with the normal-conducting ion source and radio-frequency quadrupole. In April 2021, the full FRIB driver linear accelerator (linac) was commissioned, with heavy ion beams accelerated to energies above 200 MeV/nucleon by 324 superconducting radiofrequency (SRF) resonators operating at 2 K and 4 K with liquid-helium cooling. In preparation for high-power operation, a liquid lithium charge stripper was commissioned with heavy ion beams up to uranium-238, followed by the simultaneous acceleration of multiple-charge-state heavy ion beams to energies above 200 MeV/nucleon. In December 2021, selenium-84 was produced with the FRIB target using a krypton-86 primary beam, demonstrating FRIB’s capability for scientific discovery.
The Entrepreneurial Intention of Algerian Students: Between Disillusionment of the Entrepreneurial Climate and Self-Confidence
Authors: Tounés Azzedine , Mahmoudi Mourad 
Published: March 2022

This article studies the entrepreneurial intention of Algerian students to explain the weakness in business creation in the country. Theoretical and empirical evidence on this subject is scarce, particularly among young Algerians. By combining two dominant research trends in the field of entrepreneurship, namely an approach based on contextual factors, and one based on individual characteristics, we examined the impact of perceived entrepreneurial climate and entrepreneurial self-efficacy on Algerian students’ entrepreneurial intentions. Our study, contextualized in the student environment, aims to analyze how entrepreneurship education moderated the relationship between entrepreneurial self-efficacy and entrepreneurial intention. Based on a sample of 302 students, our survey yielded two important results. The first was the negative effect of perceived entrepreneurial climate on entrepreneurial intention. The second was that as a moderating factor, entrepreneurship education did not reinforce the significant direct influence of entrepreneurial self-efficacy on the intention to start a business among Algerian students. These insights may help improve the level of entrepreneurial intention within developing countries.
Clinical Efficacy and Safety of Percutaneous Spinal Endoscopy versus Traditional Open Surgery for Lumbar Disc Herniation: Systematic Review and Meta-Analysis
Authors: Xu Xingping , Chen Changwei , Tang Yong , Wang Fusheng , Wang Yangsheng 
Published: March 2022

Objective. Systematic analysis of the incidence of percutaneous spinal endoscopic technique and traditional open surgery for lumbar disc herniation. Methods. A randomized controlled trial (RCT) and cohort study on complications related to traditional open surgery was searched on the MEDLINE, Cochrane Library, PubMed, Web of Science, Chinese journal full-text database (CNKI), Wanfang, and Embase database. Language is not limited. The quality of each study was evaluated, various complications were compiled into electronic baseline tables, and the data from these studies were available. Meta-analysis and synthesis were performed with the RevMan 5.3 software to evaluate the statistical significance of both surgical techniques in terms of various complications. Results. 12 studies were eventually included, and a total of 2,797 patients were included in the analysis. Meta-analysis results showed that there was no statistical difference in postoperative paresthesia between percutaneous spinal endoscopy and traditional open surgery (OR = 1.17, 95% CI (0.82, 1.66),

P

= 0.38, I2 = 0%, Z = 0.88), direct nerve root damage (OR = 0.79, 95% CI (0.58, 1.07),

P

= 0.13, I2 = 73%, Z = 1.52), and intraoperative hemorrhage and hematoma formation (OR = 1.00, 95% CI (0.67, 1.48),

P

= 0.99, I2 = 0%, Z = 0.02), but there was a statistical difference in disc recurrence (OR = 2.24, 95% CI (1.56, 3.21),

P

< 0.0001, I2 = 81%, Z = 4.39). Conclusion. Compared with the traditional open surgical treatment of lumbar disc herniation, percutaneous spinal endoscopic technology has obvious advantages in reducing nerve root injury, dural injury, and surgical area wound complications, but it is limited to preventing the technical characteristics of the surgical site, which is worse than that of open surgery.
Quantifying Differences in Remaining Life Expectancy after Cancer Diagnosis, Aboriginal and Torres Strait Islanders, and Other Australians, 2005–2016
Authors: Dasgupta Paramita , Andersson Therese M.-L. , Garvey Gail , Baade Peter D. 
Published: March 2022

AbstractBackground:This study quantified differences in remaining life expectancy (RLE) among Aboriginal and Torres Strait Islander and other Australian patients with cancer. We assessed how much of this disparity was due to differences in cancer and noncancer mortality and calculated the population gain in life years for Aboriginal and Torres Strait Islanders cancer diagnoses if the cancer survival disparities were removed.Methods:Flexible parametric relative survival models were used to estimate RLE by Aboriginal and Torres Strait Islander status for a population-based cohort of 709,239 persons (12,830 Aboriginal and Torres Strait Islanders), 2005 to 2016.Results:For all cancers combined, the average disparity in RLE was 8.0 years between Aboriginal and Torres Strait Islanders (12.0 years) and other Australians (20.0 years). The magnitude of this disparity varied by cancer type, being &gt;10 years for cervical cancer versus &lt;2 years for lung and pancreatic cancers. For all cancers combined, around 26% of this disparity was due to differences in cancer mortality and 74% due to noncancer mortality. Among 1,342 Aboriginal and Torres Strait Islanders diagnosed with cancer in 2015 an estimated 2,818 life years would be gained if cancer survival disparities were removed.Conclusions:A cancer diagnosis exacerbates the existing disparities in RLE among Aboriginal and Torres Strait Islanders. Addressing them will require consideration of both cancer-related factors and those contributing to noncancer mortality.Impact:Reported survival-based measures provided additional insights into the overall impact of cancer over a lifetime horizon among Aboriginal and Torres Strait Islander peoples.
Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma
Authors: Schuler Martin , Zimmer Lisa , Kim Kevin B. , Sosman Jeffrey A. , Ascierto Paolo A. , Postow Michael A. , De Vos Filip Y.F.L. , van Herpen Carla M.L. , Carlino Matteo S. , Johnson Douglas B. , Berking Carola , Reddy Micaela B. , Harney Allison S. , Berlin Jordan D. , Amaria Rodabe N. 
Published: March 2022

Abstract

Purpose:
Enhanced MAPK pathway signaling and cell-cycle checkpoint dysregulation are frequent in NRAS-mutant melanoma and, as such, the regimen of the MEK inhibitor binimetinib and the selective CDK4/6 inhibitor ribociclib is a rational combination.

Patients and Methods:
This is a phase Ib/II, open-label study of ribociclib + binimetinib in patients with NRAS-mutant melanoma (NCT01781572). Primary objectives were to estimate the MTD/recommended phase II dose (RP2D) of the combination (phase Ib) and to characterize combination antitumor activity at the RP2D (phase II). Tumor genomic characterization and pharmacokinetics/pharmacodynamics were also evaluated.

Results:
Ten patients (16.4%) experienced dose-limiting toxicities in cycle 1 of phase Ib. Overall response rate in the phase II cohort (n = 41) for the selected RP2D (binimetinib 45 mg twice daily + ribociclib 200 mg once daily, 21 days on/7 days off) was 19.5% [8/41; 95% confidence interval (CI), 8.8–34.9]. The response rate was 32.5% (13/40; 95% CI, 20.1–48.0) in patients with NRAS mutation with concurrent alterations of CDKN2A, CDK4, or CCND1. Median progression-free survival was 3.7 months (95% CI, 3.5–5.6) and median overall survival was 11.3 months (95% CI, 9.3–14.2) for all patients. Common treatment-related toxicities included creatine phosphokinase elevation, rash, edema, anemia, nausea, diarrhea, and fatigue. Pharmacokinetics and safety were consistent with single-agent data, supporting a lack of drug–drug interaction.

Conclusions:
Ribociclib + binimetinib can be safely administered and is clinically active in patients with NRAS-mutant melanoma. Co-mutations of cell-cycle genes may define a population with greater likelihood of treatment benefit.
See related commentary by Moschos, p. 2977
Is the Pannexin-1 Channel a Mechanism Underlying Hypertension in Humans? a Translational Study of Human Hypertension
Authors: Gliemann Lasse , Tamariz-Ellemann Andrea , Collin Hansen Camilla , Svare Ehlers Thomas , Møller Sophie , Hellsten Ylva 
Published: March 2022

Background:
In preclinical models, the pannexin-1 channel has been shown to be involved in blood pressure regulation through an effect on peripheral vascular resistance. Pannexin-1 releases ATP, which can activate constrictive purinergic receptors on the smooth muscle cells. Pannexin-1 opening is proposed to be mediated by α-adrenergic receptors to potentiate sympathetic constriction. This positions pannexin-1 as a putative pharmacological target in blood pressure regulation in humans. The aim was to provide the first translational evidence for a role of pannexin-1 in essential hypertension in humans by use of an advanced invasive mechanistic approach.

Methods:
Middle-aged stage-1 hypertensive (n=13; 135.7±6.4 over 83.7±3.7 mm Hg) and normotensive men (n=12; 117.3±5.7 over 72.2±3.5 mm Hg) were included. Blood pressure and leg vascular resistance were determined during femoral arterial infusion of tyramine (α-adrenergic receptor stimulation), sodium nitroprusside, and acetylcholine. Measurements were made during control conditions and with pannexin-1 blockade (3000 mg probenecid). Expression of Pannexin-1, purinergic- and α-adrenergic receptors in skeletal muscle biopsies was determined by Western blot.

Results:

The changes in leg vascular resistance in response to tyramine (+289% versus +222%), sodium nitroprusside (−82% versus −78%) and acetylcholine (−40% versus −44%) infusion were not different between the 2 groups (
P
>0.05) and pannexin-1 blockade did not alter these variables (
P
>0.05). Expression of pannexin-1 and of purinergic- and α-adrenergic receptors was not different between the 2 groups (
P
>0.05).

Conclusions:
Contrary to our hypothesis, the data demonstrate that pannexin-1 does not contribute to the elevated blood pressure in essential hypertension, a finding, which also opposes that reported in preclinical models.